Twin Intellia Readouts Further Bolster CRISPR Platform

 
• By Alaric DeArment

The company presented interim data for NTLA-2002 in hereditary angioedema, along with interim data for Regeneron-partnered NTLA-2001 in transthyretin amyloidosis with cardiomyopathy. The company plans a rapid expansion of its programs.

Intellia announced data for NTLA-2002 and Regeneron-partnered NTLA-2001 • Source: Shutterstock

More from Strategy

More from Business